Macrogen, a leading precision medicine biotech company under the leadership of Changhoon Kim, proudly announced that its European arm, Macrogen Europe, has achieved distinction as one of the '2023 Top 10 Sanger Sequencing Services Company' by the esteemed US life sciences journal, 'Life Sciences Review.' This recognition, a testament to the company's commitment to cutting-edge technologies and exceptional service, annually acknowledges innovative companies driving advancements in science and biological services.

Established in 2008, Macrogen Europe has been instrumental in providing genome analysis services to over 3,000 research clients across Europe and Africa. Specializing in Sanger sequencing (CES) techniques, the company operates nine genome centers, efficiently handling over 25,000 samples every week.

Since 2019, Macrogen Europe has owned and operated its 'Next-Generation Sequencing (NGS)' equipment, catering to high-throughput sequencing projects. Additionally, the company consistently augments its support offerings for global researchers, integrating state-of-the-art technologies like Illumina's NovaSeq X platform, currently recognized as the world's largest genome analysis device.

Recent strides include the introduction of 'plasmid sequencing,' leveraging technology from the UK-based biotech company, Oxford Nanopore. This advancement in services focuses on plasmids, pivotal in gene therapies and editing tools. Macrogen Europe envisions a streamlined service model, allowing customers to conveniently dispatch samples via an online platform and receive comprehensive reports within days.

Bong-Jo Kim, the head of Macrogen Europe, emphasized, "Our sequencing services are tailored to mitigate temporal challenges faced by researchers, ensuring maximum efficiency amid project timelines." He continued, "We consistently engage in in-depth consultations with clients, providing customized solutions that empower them to attain the flexibility and efficiency essential for their research endeavors." Looking forward, Kim added, "Our plans include establishing country-specific branches and broadening our service spectrum from Sanger sequencing to encompass NGS, thus enhancing accessibility and support for our clientele."